Search Results - "Yeoh, Aileen Ying Yan"

BNT162b2 vaccine induced variant-specific immunity, safety and risk of Omicron breakthrough infection in children aged 5 to 11 years: a cohort study by Yung, Chee Fu, Le Bert, Nina, Kam, Kai Qian, Saffari, Seyed Ehsan, Tan, Chee Wah, Mah, Yun Yan, Zhang, Jinyan, Yeoh, Aileen Ying-Yan, Zhu, Feng, Hariharaputran, Smrithi, Chong, Chia Yin, Bertoletti, Antonio, Wang, Linfa

“…There is little information on BNT162b2 vaccine-induced variant-specific immunogenicity, safety data and dynamics of breakthrough infections in pediatric…”
Get full text

Single-shot dendritic cell targeting SARS-CoV-2 vaccine candidate induces broad, durable and protective systemic and mucosal immunity in mice by Cheang, Nicholas You Zhi, Tan, Kai Sen, Tan, Peck Szee, Purushotorma, Kiren, Yap, Wee Chee, Tullett, Kirsteen McInnes, Chua, Benson Yen Leong, Yeoh, Aileen Ying-Yan, Tan, Caris Qi Hui, Qian, Xinlei, Chen, Huixin, Tay, Douglas Jie Wen, Caminschi, Irina, Tan, Yee Joo, Macary, Paul Anthony, Tan, Chee Wah, Lahoud, Mireille Hanna, Alonso, Sylvie

“…Current coronavirus disease 2019 vaccines face limitations including waning immunity, immune escape by severe acute respiratory syndrome coronavirus 2…”
Get more information

Comparative neutralisation profile of SARS-CoV-2 omicron subvariants BA.2.75 and BA.5 by Tan, Chee-Wah, Lim, Beng-Lee, Young, Barnaby E, Yeoh, Aileen Ying-Yan, Yung, Chee-Fu, Yap, Wee-Chee, Althaus, Thomas, Chia, Wan-Ni, Zhu, Feng, Lye, David Chien, Wang, Lin-Fa

Get full text

Priming conditions shape breadth of neutralizing antibody responses to sarbecoviruses by Jia, Janice Zhirong, Tan, Chee Wah, Cheng, Samuel M. S., Gu, Haogao, Yeoh, Aileen Ying Yan, Mok, Chris Ka Pun, Wang, Yanqun, Zhao, Jincun, Leung, Nancy H. L., Cowling, Benjamin J., Poon, Leo L. M., Hui, David S. C., Wang, Linfa, Peiris, Malik, Valkenburg, Sophie A.

“…Vaccines that are broadly cross-protective against current and future SARS-CoV-2 variants of concern (VoC) or across the sarbecoviruses subgenus remain a…”
Get full text

SARS-CoV-2 Omicron variant emerged under immune selection by Tan, Chee Wah, Chia, Wan Ni, Zhu, Feng, Young, Barnaby E., Chantasrisawad, Napaporn, Hwa, Shi-Hsia, Yeoh, Aileen Ying-Yan, Lim, Beng Lee, Yap, Wee Chee, Pada, Surinder Kaur M. S., Tan, Seow Yen, Jantarabenjakul, Watsamon, Toh, Lim Kai, Chen, Shiwei, Zhang, Jinyan, Mah, Yun Yan, Chen, Vivian Chih-Wei, Chen, Mark I-C, Wacharapluesadee, Supaporn, Sigal, Alex, Putcharoen, Opass, Lye, David Chien, Wang, Lin-Fa

“…The SARS-CoV-2 Omicron variant (B.1.1.529 lineage) escapes antibodies that neutralize the ancestral virus. We tested human serum panels from participants with…”
Get full text

Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor by Chia, Wan Ni, Tan, Chee Wah, Tan, Aaron Wai Kit, Young, Barnaby, Starr, Tyler N, Lopez, Ester, Fibriansah, Guntur, Barr, Jennifer, Cheng, Samuel, Yeoh, Aileen Ying-Yan, Yap, Wee Chee, Lim, Beng Lee, Ng, Thiam-Seng, Sia, Wan Rong, Zhu, Feng, Chen, Shiwei, Zhang, Jinyan, Kwek, Madeline Sheng Si, Greaney, Allison J, Chen, Mark, Au, Gough G, Paradkar, Prasad N, Peiris, Malik, Chung, Amy W, Bloom, Jesse D, Lye, David, Lok, Sheemei, Wang, Lin-Fa

“…The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern such as Omicron hampered efforts in controlling the ongoing…”
Get full text

Antibody response of heterologous vs homologous mRNA vaccine boosters against the SARS-CoV-2 Omicron variant: interim results from the PRIBIVAC study, A Randomized Clinical Trial by Poh, Xuan Ying, Tan, Chee Wah, Lee, I. Russel, Chavatte, Jean-Marc, Fong, Siew-Wai, Prince, Tessa, Hartley, Catherine, Yeoh, Aileen Ying-Yan, Rao, Suma, Chia, Po Ying, Ong, Sean WX, Lee, Tau Hong, Sadarangani, Sapna P., Lin, Ray JH, Lim, Clarissa, Teo, Jefanie, Lim, Daniel RX, Chia, Wanni, Hiscox, Julian A., Ng, Lisa F.P., Ren, Ee Chee, Lin, Raymond TP, Renia, Laurent, Lye, David Chien, Wang, Lin-Fa, Young, Barnaby E

Get full text

Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial by Poh, Xuan Ying, Torres-Ruesta, Anthony, Yoong, Terence, Wong, Nathan, Tan, Chee Wah, Rouers, Angeline, Chavatte, Jean-Marc, Goh, Yun Shan, Rao, Suma, Chia, Po Ying, Ong, Sean W.X., Lee, Tau Hong, Sadarangani, Sapna P., Lin, Ray J.H., Neo, Vanessa, Kam, Isaac Kai Jie, Huang, Yuling, Hor, Pei Xiang, Loh, Chiew Yee, Yeoh, Aileen Ying-Yan, Lim, Daniel R.X., Chia, Wanni, Ren, Ee Chee, Lin, Raymond T.P., Fong, Siew-Wai, Renia, Laurent, Lye, David Chien, Wang, Lin-Fa, Ng, Lisa F.P., Young, Barnaby E.

“…BBV152 (Covaxin™) is a whole-virion inactivated SARS-CoV-2 vaccine mixed with an immune adjuvant. We aimed to compare immune responses after booster…”
Get full text

Distinctive serotypes of SARS-related coronaviruses defined by convalescent sera from unvaccinated individuals by Tan, Chee Wah, Zhu, Feng, Chia, Wan Ni, Young, Barnaby E, Yeoh, Aileen Ying Yan, Althaus, Thomas, Yung, Chee Fu, Yap, Wee Chee, Lim, Beng Lee, Chen, Mark I-C, Zhang, Jinyan, Mah, Yun Yan, Voiglio, Eric, Sigal, Alex, Huo, Jianxin, Xu, Shengli, Tan, Yee Joo, Lam, Kong-Peng, Lye, David, Wang, Lin-Fa

“…Multiple Omicron sub-lineages have emerged, with Omicron XBB and XBB.1.5 subvariants becoming the dominant variants globally at the time of this study. The key…”
Get full text